Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Kathleen N Moore,Antoine Angelergues,Gottfried E Konecny,Yolanda García,Susana Banerjee,Domenica Lorusso,Jung-Yun Lee,John W Moroney,Nicoletta Colombo,Andrzej Roszak,Jacqueline Tromp,Tashanna Myers,Jeong-Won Lee,Mario Beiner,Casey M Cosgrove,David Cibula,Lainie P Martin,Renaud Sabatier,Joseph Buscema,Purificación Estévez-García,Lan Coffman,Shibani Nicum,Linda R Duska,Sandro Pignata,Fernando Gálvez,Yuemei Wang,Michael Method,Anna Berkenblit,Diana Bello Roufai,Toon Van Gorp,Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups,Katheen N Moore,Gina Mantia-Smaldone,Erika Hamilton,Andrea Jewell,Richard Boothby,Charles Leath,Michael Gold,Sudarshan Sharma,Peter Rose,Jason Wright,Alessandro Santin,James Barter,Robert Morris,Brian Orr,Mary Gordinier,Katrina Wade,Susan Zweizig,Matthew Oliver,Ying Zhuo,Daniel Sonnenburg,Michael Teneriello,Noelle Cloven,Donald Richards,Bradley Monk,K Shawn LyBarger,Ramey Littell,Destin Black,Christine Lee,Sharyn Lewin,Michael Sundborg,Kimberly Resnick,Megan Indermaur,Robert H Wenham,Gerardo Colon-Otero,John Schorge,Eleonora Teplinsky,Victoria Galvan-Turner,Suresh Ratnam,Urszula Sobol,Gina Westhoff,James Burke,Charles Anderson,Robert Marsh,Erin Salinas,Kevin Schuler,Cynthia Chua,Caesar Tin-U,Kristy Ward,Terri Pustilnik,Cheryl Aylesworth,Melissa Hardesty,Setsuko Chambers,Antonio Santillan-Gomez,Jessica Thomes Pepin,Ling Ma,Timothy Moore,Thomas Krivak,Edwin Alvarez,Alberto Mendivil,Mae Zakhour,Joseph Lucci,Grant Harrer,Rebecca Liu,Michael Carney,Lowell Hart,Gail Wright,Daniel Spitz,Kristina Butler,Saravut Weroha,Margarett Ellison,Emily Whitman,Peter Lim,Xiaohua Wu,Ge Lou,Bairong Xia,Danbo Wang,Ke Wang,An Lin,Youguo Chen,Yi Huang,Hui Qiu,Xin Wang,Ruifang An,Guiling Li,Hongwu Wen,Kun Song,Yunong Gao,Qing Chen,Zhiqing Liang,Jihong Liu,Li Wang,Liangqing Yao,Ying Yue,Shuzhong Yao,Hui Zhang,Yu Zhang,Lipai Chen,Yumei Wu,Nikolaus de Gregorio,Claudia Haenle,Fabienne Schochter,Felix Hilpert,Fabian Trillsch,Pauline Wimberger,Martina Gropp-Meier,Barbara Schmalfeldt,Gerd Bauerschmitz,Holger Bronger,Antje Lehnert,Tanja Fehm,Lars Hanker,Hermann Voß,Maximilian Klar,Nurgül Akyol,Alexander Mustea,Ivo Meinhold-Heerlein,Ahmed El-Balat,Coriolan Lebreton,Anne Floquet,Dominique Berton-Rigaud,Jerome Alexandre,Alexandra Leary,Laurence Gladieff,Elsa Kalbacher,Benoit You,Anne-Claire Hardy-Bessard,Stéphanie Bécourt,Marie-Christine Kaminsky,Olivier Tredan,Claudio Zamagni,Elena Geuna,Giorgio Valabrega,Germana Tognon,Annamaria Ferrero,Fausto Roila,Alessandra Bologna,Paolo Scollo,Antonio Ardizzoia,Giulia Tasca,Paolo Zola,Margarita Romeo Marin,Arantzazu Barquín,Jeronimo Martinez,Alfonso Yubero,Ana Santaballa,Nuria Ruiz,Santiago González,María Merino Salvador,J Cueva,Rowan Miller,Rosalind Glasspool,Charlie Gourley,Clare Barlow,Gordon Jayson,Lucy McAvan,Sarah Ayers,Kate Scatchard,Shanthini Crusz,Diane Provencher,Prafull Ghatage,Lucy Gilbert,Allan Covens,Amit Oza,Johanne Weberpals,Sophia Pin,Paul Bessette,Gary Richardson,Connie Irene Diakos,Martin Oehler,Anthony Bonaventura,Yeh Chen Lee,Kate Webber,Andrew Dean,Marlies De Bock,Wim Demey,Sevilay Altintas,Vincent Renard,Greet Huygh,Ronnie Shapira,Shani Breuer,Inbar Ben-Shachar,Adelya Yachnin,Tally Levy,Wieslawa Bednarek,Magdalena Sikorska,Dagmara Klasa-Mazurkiewicz,Anita Chudecka-Głaz,Pawel Derlatka,Yong-Man Kim,Jae-Weon Kim,Myong Cheol Lim,Yong-Beom Kim,Dinara Ryspayeva,Zub Oleksandr,Piatnytska Tetiana,Vladyslav Sukhin,Anna Kryzhanivska,Viktor Paramonov,Hristo Dechev,Nataliya Stefanova,Jeliazko Arabadjiev,Nikolay Conev,Bozhil Robev,Luís António Marques da Costa,Maria de Lurdes Batarda,Mafalda Sofia Rosado Casa-Nova Peres,Joana Bordalo E Sá,Mónica Nave,Ingrid Boere,Nelleke Ottevanger,Roy Lalisang,Mikhail Dvorkin,Elena Poddubskaya,Oleg Lipatov,Olga Mikheeva,Jaroslav Klat,Markéta Pospíšková,Peng-Hui Wang,Chih-Long Chang,Sheng-Mou Hsiao,Marijana Milovic-Kovacevic,Aljoša Mandić,Jasmina Nedović
DOI: https://doi.org/10.1056/NEJMoa2309169
2023-12-07
Abstract:Background: Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United States. Methods: We conducted a phase 3, global, confirmatory, open-label, randomized, controlled trial to compare the efficacy and safety of MIRV with the investigator's choice of chemotherapy in the treatment of platinum-resistant, high-grade serous ovarian cancer. Participants who had previously received one to three lines of therapy and had high FRα tumor expression (≥75% of cells with ≥2+ staining intensity) were randomly assigned in a 1:1 ratio to receive MIRV (6 mg per kilogram of adjusted ideal body weight every 3 weeks) or chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan). The primary end point was investigator-assessed progression-free survival; key secondary analytic end points included objective response, overall survival, and participant-reported outcomes. Results: A total of 453 participants underwent randomization; 227 were assigned to the MIRV group and 226 to the chemotherapy group. The median progression-free survival was 5.62 months (95% confidence interval [CI], 4.34 to 5.95) with MIRV and 3.98 months (95% CI, 2.86 to 4.47) with chemotherapy (P<0.001). An objective response occurred in 42.3% of the participants in the MIRV group and in 15.9% of those in the chemotherapy group (odds ratio, 3.81; 95% CI, 2.44 to 5.94; P<0.001). Overall survival was significantly longer with MIRV than with chemotherapy (median, 16.46 months vs. 12.75 months; hazard ratio for death, 0.67; 95% CI, 0.50 to 0.89; P = 0.005). During the treatment period, fewer adverse events of grade 3 or higher occurred with MIRV than with chemotherapy (41.7% vs. 54.1%), as did serious adverse events of any grade (23.9% vs. 32.9%) and events leading to discontinuation (9.2% vs. 15.9%). Conclusions: Among participants with platinum-resistant, FRα-positive ovarian cancer, treatment with MIRV showed a significant benefit over chemotherapy with respect to progression-free and overall survival and objective response. (Funded by ImmunoGen; MIRASOL ClinicalTrials.gov number, NCT04209855.).